Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869403 | 0.98 | EGFR (0.43) | EGFRPIM1KDM4ESMN1; SMN2KDM1A | |
| SCHEMBL30869590 | 0.94 | PIM1 (0.45) | EGFRPIM1TSHRLMNAALDH1A1 | |
| SCHEMBL30869654 | 0.91 | ALDH1A1 (0.43) | EGFRKDM4ESMN1; SMN2KDM1ATSHR | |
| SCHEMBL30869621 | 0.90 | TSHR (0.50) | EGFRPIM1KDM4ESMN1; SMN2TSHR | |
| SCHEMBL30869412 | 0.90 | ALDH1A1 (0.42) | EGFRKDM4ESMN1; SMN2KDM1ATSHR | |
| SCHEMBL30869737 | 0.86 | KDM1A (0.51) | EGFRPIM1KDM4ESMN1; SMN2KDM1A | |
| SCHEMBL30869671 | 0.85 | ALDH1A1 (0.41) | EGFRKDM4EKDM1AALDH1A1 | |
| SCHEMBL30869519 | 0.84 | ALDH1A1 (0.41) | EGFRKDM4ESMN1; SMN2KDM1AALDH1A1 | |
| SCHEMBL30869692 | 0.83 | PIM1 (0.33) | PIM1 | |
| SCHEMBL30869389 | 0.82 | AHR (0.34) | PIM1KDM4ETSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054661-A2 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | EGFR 1355/4885PIM1 4177/4885KDM4E 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.